Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy
Laird J, Lok B, Siu C, Cahlon O, Khan A, McCormick B, Powell S, Cody H, Wen H, Ho A, Braunstein L. Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy. Annals Of Surgical Oncology 2017, 25: 154-163. PMID: 29094250, PMCID: PMC5827945, DOI: 10.1245/s10434-017-6209-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNeoplasms, Second PrimaryProportional Hazards ModelsRadiotherapy, AdjuvantSurvival RateConceptsDisease-free survivalBreast-conserving therapyBreast tumor recurrenceTrue recurrenceNew primarySitu componentOverall survivalTumor sizeTumor recurrenceFive-year disease-free survivalTR groupCox proportional hazards regression modelLower disease-free survivalWorse disease-free survivalProportional hazards regression modelsSimultaneous distant metastasesKaplan-Meier methodHazards regression modelsLog-rank testAxillary surgeryDFS eventsNode involvementLymphovascular invasionMargin statusUnresectable recurrenceUnravelling the biology of SCLC: implications for therapy
Sabari J, Lok B, Laird J, Poirier J, Rudin C. Unravelling the biology of SCLC: implications for therapy. Nature Reviews Clinical Oncology 2017, 14: 549-561. PMID: 28534531, PMCID: PMC5843484, DOI: 10.1038/nrclinonc.2017.71.Peer-Reviewed Original ResearchConceptsBiology of SCLCHigh-grade neuroendocrine tumorsPARP inhibitor veliparibImmune checkpoint blockadeEncouraging clinical activityPoor overall survivalHigh mutational burdenImmune checkpoint proteinsZeste homologue 2Antibody-drug conjugatesOverall survivalRovalpituzumab tesirineLung cancerNeuroendocrine tumorsClinical trialsClinical activityMutational burdenNew therapiesTherapeutic targetingProtein 3SCLCHomologue 2PatientsPromising activityTherapy